Compare CURI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURI | CCCC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 177.4M |
| IPO Year | N/A | 2020 |
| Metric | CURI | CCCC |
|---|---|---|
| Price | $3.25 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.00 | ★ $7.25 |
| AVG Volume (30 Days) | 460.5K | ★ 1.4M |
| Earning Date | 03-11-2026 | 02-27-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,595,000.00 | $30,108,000.00 |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $7.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.62 | N/A |
| 52 Week Low | $2.06 | $1.09 |
| 52 Week High | $7.15 | $3.65 |
| Indicator | CURI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 34.03 | 43.91 |
| Support Level | $3.03 | $1.74 |
| Resistance Level | $3.40 | $1.90 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 16.46 | 40.56 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.